Wang Helen H, Wang David Q-H
Department of Medicine, Liver Center and Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School and Harvard Digestive Diseases Center, Boston, MA 02215, USA.
Hepatology. 2005 Oct;42(4):894-904. doi: 10.1002/hep.20867.
It has been found that polymorphisms in the apolipoprotein (APO)-B gene are associated with cholesterol gallstones in humans. We hypothesized that APO-B plays a major regulatory role in the response of biliary cholesterol secretion to high dietary cholesterol and contributes to cholesterol gallstone formation. In the present study, we investigated whether lack of expression of intestinal Apob48 or Apob100 reduces susceptibility to cholesterol gallstones by decreasing intestinal absorption and biliary secretion of cholesterol in male mice homozygous for an "APO-B48 only" allele (Apob(48/48)), an "APO-B100 only" allele (Apob(100/100)), or a wild-type APO-B allele (Apob+/+) before and during an 8-week lithogenic diet. We found that cholesterol absorption was significantly decreased as a result of the APO-B48 deficiency in Apob(100/100) mice compared with wild-type and Apob(48/48) mice, regardless of whether chow or the lithogenic diet was administered. Consequently, hepatic cholesterol synthesis was significantly increased in Apob(100/100) mice compared with wild-type and Apob(48/48) mice. On chow, the APO-B100 deficiency in Apob(48/48) mice with reduced plasma levels of LDL/VLDL--but not HDL cholesterol--induced relative hyposecretion of biliary bile salts and phospholipids accompanying normal biliary cholesterol secretion. Compared with Apob(48/48) and wild-type mice, lithogenic diet-fed Apob(100/100) mice displayed significantly lower secretion rates of biliary cholesterol, but not phospholipid or bile salts, which results in significant decreases in prevalence rates, numbers, and sizes of gallstones. In conclusion, absence of expression of intestinal Apob48, but not Apob100, reduces biliary cholesterol secretion and cholelithogenesis, possibly by decreasing intestinal absorption and hepatic bioavailability.
已发现载脂蛋白(APO)-B基因多态性与人类胆固醇胆结石有关。我们推测,APO-B在胆汁胆固醇分泌对高膳食胆固醇的反应中起主要调节作用,并促成胆固醇胆结石的形成。在本研究中,我们调查了在为期8周的致石性饮食之前和期间,“仅APO-B48”等位基因(Apob(48/48))、“仅APO-B100”等位基因(Apob(100/100))或野生型APO-B等位基因(Apob+/+)的雄性纯合小鼠中,肠道Apob48或Apob100表达缺失是否通过降低肠道胆固醇吸收和胆汁胆固醇分泌来降低胆固醇胆结石易感性。我们发现,与野生型和Apob(48/48)小鼠相比,Apob(100/100)小鼠中由于APO-B48缺乏,胆固醇吸收显著降低,无论给予普通饲料还是致石性饮食。因此,与野生型和Apob(48/48)小鼠相比,Apob(100/100)小鼠肝脏胆固醇合成显著增加。在普通饲料喂养下,Apob(48/48)小鼠中APO-B100缺乏导致血浆低密度脂蛋白/极低密度脂蛋白水平降低,但高密度脂蛋白胆固醇水平未降低,同时伴随正常胆汁胆固醇分泌,引起胆汁胆盐和磷脂相对分泌不足。与Apob(48/48)和野生型小鼠相比,致石性饮食喂养的Apob(100/100)小鼠胆汁胆固醇分泌率显著降低,但磷脂或胆盐分泌率未降低,这导致胆结石患病率、数量和大小显著降低。总之,肠道Apob48而非Apob100表达缺失可能通过降低肠道吸收和肝脏生物利用度来减少胆汁胆固醇分泌和胆石形成。